Relapsed/refractory (R/R) diffuse large B-cell lymphoma research hub

A first-in-human, open-label, clinical study to assess the safety, tolerability, and activity of OT-C001 (amplified/activated allogenic natural killer cells) in patients with relapsed/refractory diffuse large B-cell lymphoma

This study is looking at a new treatment called OT-C001 for people with a type of blood cancer called diffuse large B-cell lymphoma. This cancer has come back or not responded to previous treatments. It's a very early study to see if the treatment is safe and how it works in humans.